Department of Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV, United States.
Dr. D.Y. Patil Medical College & Research, Maharashtra, India.
Cancer Treat Res Commun. 2021;27:100357. doi: 10.1016/j.ctarc.2021.100357. Epub 2021 Mar 17.
Ponatinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphoblastic leukemia. Common adverse effects of ponatinib include neutropenia, arterial thrombosis, and hypertension. We describe a 49-year-old woman who developed panniculitis after brief treatment with ponatinib. In addition, we summarize other studies describing TKI-associated panniculitis.
波那替尼是一种酪氨酸激酶抑制剂（TKI），获批用于治疗费城染色体阳性慢性髓性白血病和急性淋巴细胞白血病。波那替尼的常见不良反应包括中性粒细胞减少症、动脉血栓形成和高血压。我们描述了一位 49 岁女性在短暂使用波那替尼治疗后发生脂膜炎。此外，我们还总结了其他描述 TKI 相关脂膜炎的研究。
